Avelumab in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||29/10/2019|
|Rapid review completed||02/01/2020|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of avelumab and axitinib compared with the current standard of care.|